Day: January 10, 2022

Converge Technology Solutions Corp. Acquires Paragon Development Systems, Inc.

Written by Customer Service on January 10, 2022. Posted in Mergers And Acquisitions.

Paragon Development Systems joins Converge as the Company’s 26th acquisition TORONTO and GATINEAU, Québec, Jan. 10, 2022 (GLOBE NEWSWIRE) — Converge Technology Solutions Corp. (“Converge” or “the Company”) (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) a software-enabled IT & Cloud Solutions provider, is pleased to announce it has acquired PDS Holding Company, a Delaware corporation, and its wholly-owned subsidiaries, including Paragon Development Systems, Inc. (PDS), a Wisconsin-based organization focused on fueling digital transformation. Converge acquired PDS from Mason Wells, a private equity firm based in Milwaukee, Wisconsin. With incredible expertise supporting Enterprise Solutions, Managed Services, and true Digital Workplace platforms, Paragon Development Systems works synergistically to leverage the strength of its solution architects...

Converge Technology Solutions Corp. Acquires Paragon Development Systems, Inc.

Written by Customer Service on January 10, 2022. Posted in Mergers And Acquisitions.

ToughBuilt Industries Reports $11.9 Million in Full Year 2021 Sales Through Amazon

Written by Customer Service on January 10, 2022. Posted in Earnings Releases And Operating Results.

LAKE FOREST, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW), announced today that gross sales through Amazon.com increased by 68.5% to approximately $11.9 million for the fiscal year ended December 31, 2021, compared to approximately $7.1 million for 2020. Michael Panosian, Chief Executive Officer of ToughBuilt, commented, “We closed 2021 with significant e-commerce demand driven by our sawhorses, knee pads, and bags. Amazon continues to positively contribute to ToughBuilt’s overall revenue growth and strengthen our brand among global end users. Currently, only our legacy products are available on Amazon, which have generated outstanding reviews to-date. We believe that as more new products become available on Amazon, we will see increased online demand.” ABOUT...

AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021

Written by Customer Service on January 10, 2022. Posted in Dividend Reports And Estimates.

VALENCIA, Calif. and MELBOURNE, Australia., Jan. 10, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2021. Preliminary Results for the Quarter ended December 31 and Recent Updates:Total revenue increased 35% to $6.9 million in the quarter ended December 31, 2021, compared to $5.1 million over the same quarter in the prior year As of December 31, 2021, the Company had approximately $55.5 million in cash and cash equivalents and $49.3 million in short-term and long-term marketable securities, and no debt Effective...

Singular Genomics Partners with New England Biolabs® to Enable NEBNext® Kits for the G4 Sequencing Platform

Written by Customer Service on January 10, 2022. Posted in Public Companies.

This partnership integrates G4’s accuracy, speed, flexibility and power with the NEBNext DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers LA JOLLA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with New England Biolabs (NEB®) to validate its NEBNext kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform. High-quality, high-yield library preparation is a critical first step towards optimizing NGS workflows. NEB is a recognized leader in the discovery and production of enzymes for molecular biology applications with renowned products in sample preparation for NGS....

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

Written by Customer Service on January 10, 2022. Posted in Public Companies.

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead. Key 2021 Financial AchievementsInitial public offering: On October 13, Cognition closed its upsized IPO and, in mid-November, the underwriters’ overallotment option was exercised to purchase additional shares of the Company’s common stock, bringing aggregate gross proceeds to approximately $52 million. $45 million in NIA grants: Cognition was awarded a $30...

Singular Genomics Partners with Lexogen to Enable RNA Library Prep for the G4 Sequencing Platform

Written by Customer Service on January 10, 2022. Posted in Public Companies.

This partnership integrates G4’s accuracy, speed, flexibility and power with Lexogen’s expertise in RNA library preparation kits to empower specialized workflows for customers. LA JOLLA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Lexogen to demonstrate the G4 sequencing platform’s compatibility with Lexogen’s products for RNA research, specifically the QuantSeq, CORALL and LUTHOR library preparation kits. Transcriptome analysis has long been considered essential in answering key questions in biology and medicine. As pioneers in the field of RNA science, Lexogen has enabled RNA library preparation kits that are cost-efficient,...

Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel

Written by Customer Service on January 10, 2022. Posted in Public Companies.

TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Avicanna USA Inc. together with Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointment of Stephen Kim as the Avicanna’s Chief Legal Officer & General Counsel. Mr. Kim comes with over twenty years of legal experience with highly regulated and innovative industries. He has significant pharmaceutical industry experience and is very familiar with the complex overlay of corporate, commercial, IP, governance, compliance, and regulatory considerations associated with development, approval, and launch of multiple pharmaceutical products, which...

REPEAT — PowerTap Reports Accelerated Commercial Development of at Home Green Hydrogen Solution

Written by Customer Service on January 10, 2022. Posted in Public Companies.

AES-100 Inc. (a leading clean hydrogen technology company) developing transformational direct-to-consumer green hydrogen power unit for the common American home AES technology positioned to save government and municipalities billions in infrastructure spend Accelerated development timeline to be twice as rapid as for industrial sized application, leading to expedited commercializationTORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) — PowerTap Hydrogen Capital Corp. is pleased to announce that its 49% owned subsidiary, AES-100 Inc. (“AES”), a leading clean hydrogen technology company, has initiated design and development activities for a green-hydrogen home power unit. This unit is being sized for applications to meet the needs of average North American households, revolutionizing green power production. The global addressable market...

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Written by Customer Service on January 10, 2022. Posted in Public Companies.

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs have been approved by the FDA, the Company believes that Tempol would provide an unmet medical need because of its unique mechanism of action and safety profile. Shyam Kottilil, MBBS, Ph.D., Professor of Medicine at the University of Maryland School of Medicine (UMSOM), Chief of the Division of Clinical Care and Research at UMSOM’s Institute...

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Day: January 10, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice